CN
EN
-
What is a pseudovirus?
- A pseudovirus refers to a virus particle that has been artificially modified. These modified virus particles retain some of their original characteristics while becoming non-infectious pseudovirus particles. In the prevention and control of viral infectious diseases, inhibiting viral entry into cells using small molecules, neutralizing antibodies, etc., is a critical step.
Pseudoviruses play a unique role in viral entry inhibition research.
Compared to “real” viruses, pseudoviruses are safer. Even pseudoviruses corresponding to high-risk viruses do not require operations in high biosafety level (BSL-3/BSL-4) laboratories. Taking the DIFF-H5N1 pseudovirus as an example, DIFF Biotech inserted reporter genes such as eGFP or Luciferase to form a pseudovirus of highly pathogenic avian influenza H5N1, enhancing the convenience and objectivity of result interpretation, making it suitable for batch testing.
Compared to methods like ELISA, pseudoviruses have higher fidelity, better simulate the real infection process, and improve the credibility of results. -
Why is DIFF Biotech's screening system more accurate, even highly consistent with live virus screening?
- The principle of screening determines the high accuracy of its results. Viral infection occurs in the microenvironment of cells and is highly dependent on changes in the cellular microenvironment to affect its life cycle. Traditional screening systems do not occur within cells and rely on biochemical reactions outside of the body, making them complex and cumbersome. Therefore, they are susceptible to interference from in vitro reaction factors, difficult to standardize, and prone to misclassification and misclassification. DIFF Biotech's screening system, through the plasmid transfection process, occurs within the cell microenvironment, highly simulating the process of virus protease cutting specific recognition sites in cells, and is not affected by conventional extracellular biochemical reaction factors (temperature, pH value, enzyme concentration, metal ions, and other reaction systems). The screening system is stable and highly reproducible, thus possessing highly accurate characteristics.
-
I am an ordinary researcher without advanced equipment, funding, a team, or a laboratory. Can DIFF Biotech’s protease inhibitor screening system solve my problem?
- DIFF Biotech's protease screening system does not require complex instruments (A regular fluorescence microscope is sufficient), does not require specialized screening personnel (ability to observe GFP fluorescence is enough), does not require adding any enzyme reaction substrates, does not require purchasing reaction systems repeatedly from the market (plasmid system, which can be replicated), and does not require a biosafety laboratory (does not involve live viruses). Currently, the company is offering free access to research customers, with only 200 yuan for packaging and shipping, to solve all your problems.
-
Why is DIFF Biotech’s protease inhibitor screening system defined as the next-generation screening system?
- Because DIFF Biotech's screening system dramatically reduces the threshold for drug screening, it can be quickly popularized in preclinical drug screening, significantly shortening the discovery time of effective drugs. It is a simpler and more accurate screening system than existing screening methods. (1) No need for biosafety experiments (2) No need for in vitro expression of proteases and synthesis and labeling of their substrates (3) No need for complex equipment, instruments, and algorithms (4) No need for expensive repeat screening costs (5) No need for lengthy time costs.
-
What are the differences in principles and processes between the protease inhibitor screening system of DIFF Biotech and traditional protease inhibitor screening systems?
- The principle of traditional screening systems can be described as follows: expressing viral enzymes in vitro, purifying them, designing substrates (peptides) with specific cleavage sequences and labeling their fluorescent groups, establishing a protease reaction system, and collecting changes in fluorescent group signals-screening effective inhibitors by indirectly reflecting changes in protease activity.
The protease inhibitor screening system of DIFF Biotech constructs a plasmid system containing expressed viral protease and recombinant GFP fluorescent protein, which can make the recombinant GFP contain virus protease-specific cleavage sequences without significantly affecting GFP luminescence function. When viral protease and GFP protein with its cleavage sequence are simultaneously expressed in cells, the recombinant GFP protein will be disrupted, resulting in the loss of fluorescence signal. In terms of operation, only conventional plasmid transfection is required to observe or detect GFP fluorescence signals without additional training. The system can directly detect changes in enzyme activity with the naked eye when effective inhibitor drugs are added (fluorescence intensity is positively correlated with drug effectiveness). -
May I ask if the DIFF Biotech protease inhibitor screening system is helpful for the direction of AI pharmaceuticals?
- AI-based drug development is an important future direction, but currently, very few AI-designed drugs have been approved. This is mainly because AI models struggle to simulate the microenvironment within cells, leading to failures in later stages of drug development. DIFF Biotech's screening system is based on honest enzyme reactions occurring inside cells. It can integrate high-throughput screening methods to quickly and accurately validate the drug candidates generated by AI technology. Due to its high efficiency and accuracy, it can assist AI screening models in rapid machine learning, thereby continuously upgrading and iterating.
